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Megalin plays a critical role in the endocytosis of albumin and
other filtered low-molecular-weight proteins. Here we
studied the interaction between megalin and Disabled-2
(Dab2), an adaptor protein that binds to the cytoplasmic
domain of megalin and appears to control its trafficking. We
co-immunoprecipitated megalin and Dab2 from cultured
proximal tubule cells and identified the proteins by liquid
chromatography and tandem mass spectrometry. We found
two proteins associated with the megalin/Dab2 complex,
nonmuscle myosin heavy chain IIA (NMHC-IIA) and b-actin.
Subcellular fractionation followed by sucrose velocity
gradient separation showed that megalin, Dab2, and NMHC-
IIA existed as a complex in the same endosomal fractions. In
vitro pull-down assays demonstrated that NMHC-IIA was
bound to the carboxyl-terminal region of Dab2, but not to
megalin’s cytoplasmic domain. We then transfected COS-7
cells with plasmids that induced the expression of Dab2,
NMHC-IIA, and the megalin minireceptor, a truncated form of
megalin. Co-immunoprecipitation studies showed that the
minireceptor and NMHC-IIA co-immunoprecipitated only
with Dab2. Furthermore, the uptake of 125I-lactoferrin, an
endocytic ligand of megalin, by rat yolk sac–derived megalin-
expressing L2 cells was inhibited by blebbistatin, a specific
inhibitor of nonmuscle myosin II. Our study shows that
NMHC-IIA is functionally linked to megalin by interaction
with Dab2 and is likely involved in megalin-mediated
endocytosis in proximal tubule cells.
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Proximal tubule cells (PTC) are involved in the uptake and
degradation of glomerular-filtered proteins by receptor-
mediated endocytosis.1 This process is important for proper
metabolization of serum proteins, and also for the regulation
of urinary protein excretion (such as albuminuria), which is a
diagnostic and prognostic marker for chronic kidney disease
and an indicator of cardiovascular risks.2,3 However, the
molecular mechanisms of receptor-mediated endocytosis in
PTC have not been fully understood.
Megalin, a large (B600 kDa) member of the low-density
lipoprotein receptor family,4,5 is found in the apical region of
PTC. Megalin plays a critical role in the proximal tubular
endocytosis of glomerular-filtered low-molecular weight
proteins and albumin.6 Megalin knockout mice display
symptoms of low-molecular weight proteinuria and albumi-
nuria, as well as osteopathy.7–9 The C-terminal cytoplasmic
tail domain of megalin encodes FXNPXY motifs for
endocytosis signaling, as well as other protein interaction
motifs (SH3 and PDZ domains) and phosphorylation
sites.5,10 The cytoplasmic domain has been found to interact
specifically with a variety of adaptor proteins including
disabled-2 (Dab2),11 and others.12–16 Although these adaptor
proteins are hypothesized to function with other intracellular
proteins during megalin-mediated endocytosis, their func-
tional partners are largely unknown.
Dab2 is an intracellular adaptor protein with an N-
terminal phosphotyrosine interaction domain that binds to
the second FXNPXY motif of megalin’s cytoplasmic
domain.11,17 Dab2 co-localizes with megalin in clathrin-
coated pits and vesicles, but not in dense apical tubules or
brush border.18 Dab2 conditional knockout mice show
reduced numbers of clathrin-coated pits in PTC and also
excrete megalin ligands in the urine.19 Kidney-specific
megalin knockout mice show a nearly complete loss of
Dab2 expression in PTC.18 Reciprocally, knockout of Dab2
results in redistribution of megalin from endosomes to
microvilli.18 These findings indicate that the subcellular
localization of Dab2 requires megalin, and that Dab2 plays a
critical role in megalin trafficking in PTC.
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Recently, Dab2 was found to interact with myosin VI,20,21
the ‘unconventional myosin’—an actin-based molecular
motor expressed only in higher eukaryotes.22,23 The interac-
tion between Dab2 and myosin VI has been hypothesized to
involve the formation of clathrin-coated vesicles.23 However,
it is probable that Dab2 also interacts with other motor or
adaptor proteins, because myosin VI is known to move only
towards the minus end of actin filaments24 and additional
machinery is likely to be required for megalin trafficking.
Based on these previous findings and hypotheses, our
study was designed to identify Dab2-interacting proteins and
investigate their involvement in megalin trafficking in PTC.
Here, we report that non-muscle myosin heavy chain IIA
(NMHC-IIA) is a novel Dab2-binding protein that is
functionally linked to megalin.
RESULTS
Identification of NMHC-IIA associations with megalin and
Dab2 in PTC
Megalin and Dab2 are known to form a complex in
immortalized rat proximal tubule cells (IRPTC) and rat yolk
sac epithelium-derived L2 cells.11 To screen Dab2-interacting
proteins that may be involved in megalin trafficking in PTC,
IRPTC were used as a starting tool for the assay, and then L2
cells were used for its verification.
Megalin- and Dab2-associated protein complexes were
isolated from lysates of IRPTC by immunoprecipitation
with a polyclonal antibody raised against immunopurified rat
megalin (Supplementary Figure S1), and a polyclonal
anti-Dab2 antibody, respectively. Immunoprecipitates were
resolved by 4–15% gradient SDS-polyacrylamide gel electro-
phoresis (PAGE) and stained with SYPRO Ruby. Among the
stained proteins shown in Figure 1, the identities of megalin
and Dab2 were confirmed by immunoblot analyses (Supple-
mentary Figure S2). To identify the two proteins that
co-precipitated with either anti-megalin or anti-Dab2
antibodies, gel slices at B210 and B40 kDa in mass were
excised, digested in a trypsin solution, and the resulting
peptides were then analyzed by liquid chromatography
coupled with tandem mass spectrometers (LC-MS/MS).
Analysis of the B210 kDa band resulted in the identification
of 31 peptides whose sequences corresponded completely to
NMHC-IIA, with 20% total sequence coverage (Supplemen-
tary Figure S3). Similarly, the B40 kDa band was identified
as b-actin, with 40% total sequence coverage (Supplementary
Figure S4).
To confirm the identity of the B210 kDa protein as
NMHC-IIA, and to verify the association of this protein with
megalin and Dab2, lysates of IRPTC and L2 cells were
prepared. After incubation of the lysates with a monoclonal
anti-megalin antibody, megalin-associated immunoprecipi-
tates were analyzed by immunoblotting with anti-NMHC-IIA
and anti-Dab2 antibodies. Both NMHC-IIA and Dab2 were
detected in megalin-associated immunoprecipitates from the
two different cell lines (Figure 2, lanes 2 and 5), but not in the
control IgG immunoprecipitates (Figure 2, lanes 3 and 6).
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Figure 1 | Isolation of megalin or Dab2-associated proteins in
IRPTC lysates. Lysates from IRPTC were immunoprecipitated with
polyclonal anti-megalin, polyclonal anti-Dab2 or normal rabbit IgG.
Precipitates were resolved by 4–15% gradient SDS-PAGE, stained
with SYPRO Ruby protein gel stain, and visualized with a Typhoon
9400 scanner. TheB210 andB40 kDa bands (indicated by arrows)
were subsequently subjected to LC-MS/MS analyses and identified
as NMHC-IIA and b-actin, respectively. The closed or open circles
indicate IgG heavy or light chains, respectively. Size markers indicate
molecular mass in kilodaltons. IP, immunoprecipitation; IRPTC,
immortalized rat proximal tubule cells.
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Figure 2 | Co-immunoprecipitation of endogenous megalin,
Dab2 and NMHC-IIA from lysates of L2 yolk sac cells and
IRPTC. Immunoprecipitation (IP) was carried out using L2 cell and
IRPTC lysates with anti-megalin (20B, lanes 2 and 5) or normal
mouse IgG (lanes 3 and 6), and the precipitates were resolved by
6% SDS-PAGE followed by immunoblotting with anti-NMHC-IIA
(Biomedical Technologies) and anti-Dab2 antibodies (C-20, Santa
Cruz Biotechnology). Lanes 1 and 4: 10 mg cell lysate. Size markers
indicate molecular mass in kilodaltons.
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Also, we carried out subcellular fractionation of rat renal
cortices on sucrose density gradients to investigate the
fractions containing megalin, Dab2 and NMHC-IIA. As
shown in Figure 3a and b, these three proteins were found in
the same subcellular fractions where an endosome marker
Rab 5A was contained. To validate that the three proteins
form a complex in vivo, we next performed sucrose velocity
gradient sedimentation experiments, followed by co-immuno-
precipitation. As shown in Figure 3c and d, immunoprecipita-
tion of the heavier fractions (no. 9 and no. 11) with the
polyclonal anti-megalin revealed that the three proteins
assembled together.
Direct binding of NMHC-IIA to the C-terminal region of Dab2
in vitro but not to megalin’s cytoplasmic domain
Class II myosins are two-headed motor proteins composed of
two heavy chains and two pairs of light chains. In humans,
there are three non-muscle myosin II heavy chains (IIA, IIB,
and IIC).25 Because the N-termini of dimerized myosin II
heavy chains are known to constitute an actin-binding
domain, we hypothesized that this was the mechanism for co-
immunoprecipitation of b-actin with NMHC-IIA. However,
the molecular basis for NMHC-IIA associating with Dab2
and megalin was not known.
We used in vitro Glutathione S-transferase (GST) pull-
down assays to test whether NMHC-IIA binds directly to
Dab2 or to the cytoplasmic domain of megalin. In vitro-
translated NMHC-IIA bound to GST fused to full-length
Dab2 (GST-Dab2) (Figure 4, lane 3), but not to GST fused to
the cytoplasmic domain of megalin (Figure 4, lane 6), or GST
alone (Figure 4, lane 2). Using the same procedure, the GST-
megalin cytoplasmic domain protein did bind in vitro-
translated autosomal recessive hypercholesterolemia (ARH),
an adaptor protein of megalin12 (data not shown). In further
experiments mapping the interaction of in vitro-translated
NMHC-IIA to Dab2, NMHC-IIA bound to GST fused to the
C-terminal region of Dab2 (GST-C-Dab2) (aa 447–770)
(Figure 4, lane 4), but not to the N-terminal region (GST-N-
Dab2) (aa 1-446) (Figure 4, lane 5). Thus, NMHC-IIA binds
directly to the C-terminal region of Dab2, but not to megalin.
Link between NMHC-IIA and megalin through interactions
with Dab2 in vivo
As the C-terminal region of Dab2 binds to NMHC-IIA,
although its N-terminal phosphotyrosine interaction domain
binds to megalin’s cytoplasmic domain,11,17 we hypothesize
that one of the roles of Dab2 in vivo is to function as a
physical link connecting these two proteins. To test this
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Figure 3 | Megalin, Dab2, and NMHC-IIA form a complex in subcellular fractions of rat renal cortices. (a) The homogenate of rat renal
cortices was layered on a continuous sucrose gradient of 0.25–2.0 M. After ultracentrifugation, fractions were taken (0.5 ml each from the top
of the gradient to the bottom) and then resolved by 4–15% gradient SDS-PAGE, followed by immunoblotting with various antibodies
against the indicated proteins. (b) Immunoprecipitation (IP) was carried out using megalin-enriched fractions (no. 6 and no.7) with
polyclonal anti-megalin (lane 2), polyclonal anti-Dab2 (C-20, lane 3), or normal rabbit IgG (lane 4). The precipitates were resolved by 6% SDS-
PAGE followed by immunoblotting with polyclonal anti-megalin, anti-NMHC-IIA (Biomedical Technologies), and monoclonal anti-Dab2 (BD
BioSciences) antibodies. Lane 1: 5 ml homogenate from fraction no. 7 shown in (a). (c) Sucrose velocity gradient centrifugation. The lysate of
rat renal microsomes was layered on a continuous sucrose gradient of 5–25%. After ultracentrifugation, fractions were taken (0.5 ml each
from the top of the gradient to the bottom) and then resolved by 4–15% gradient SDS-PAGE, followed by immunoblotting with indicated
antibodies. The location of standard proteins (catalase, apoferritin, and thyroglobulin) are shown at the top of the figure. (d) IP was carried
out using indicated fractions (no. 3, 5, 7, 9, 11, 13, and 15) with polyclonal anti-rat megalin. The precipitates were resolved by 4–15%
gradient SDS-PAGE followed by immunoblotting with anti-megalin (LBD4), anti-NMHC-IIA, and anti-Dab2 antibodies. Size markers indicate
molecular mass in kilodaltons. Arrowhead indicates the loading position.
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hypothesis, plasmids encoding green fluorescent protein
(GFP)-tagged NMHC-IIA, V5-tagged Dab2 and a ‘megalin
minireceptor’ were co-transfected into COS-7 cells, which
express endogenously NMHC-IIB, but not NMHC-IIA.26
The megalin minireceptor, which is truncated to maintain the
fourth ligand-binding domain (LBD) through the cytoplas-
mic domain, has been shown to mimic the function and
trafficking of native megalin.27 Lysates prepared from the co-
transfected cells were used for immunoprecipitation analysis
with the anti-megalin or anti-GFP antibody, followed by
immunoblotting with the anti-GFP or anti-megalin antibody,
respectively (Figure 5).
In the lysates from the cells co-transfected with all the
three plasmids, GFP-NMHC-IIA was detected clearly in the
anti-megalin immunoprecipitates (Figure 5a, lane 5), and
very little NMHC-IIA precipitated from the lysates lacking
V5-tagged Dab2 (Figure 5a, lane 2; Figure 5b, lane 2). The
low-level association of the megalin minireceptor and GFP-
NMHC-IIA in the absence of transfected V5-tagged Dab2 is
supposedly due to small amounts of endogenous Dab2 in the
COS-7 cells (Figure 5a, lane 2). In a reciprocal experiment,
the megalin minireceptor was clearly detected in GFP-
immunoprecipitates when cells were co-transfected with the
three plasmids (Figure 5b, lane 5). These results indicate that
megalin associates with NMHC-IIA through interactions
with Dab2, and that megalin, Dab2, and NMHC-IIA form a
multimeric complex in co-transfected cells.
Suppression of megalin-mediated endocytosis by
blebbistatin, a specific inhibitor of non-muscle myosin II
Previous studies suggest that non-muscle myosin II plays a
role in vesicle trafficking.28–30 Non-muscle myosin II activity
is specifically inhibited by blebbistatin,31 which is cell
permeable and does not alter the activities of other
myosins.31,32 To examine whether blebbistatin affects the
endocytic function of megalin, megalin-expressing L2 cells,
with similar characteristics of PTC33 and well-established for
the analysis of megalin-mediated endocytosis34–38 were
assayed in either the presence or absence of blebbistatin
(100 mM) for the uptake of lactoferrin, an endocytic ligand of
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Figure 4 | Interaction of NMHC-IIA with the C-terminal region
of Dab2 but not with GST-megalin cytoplasmic tail domain.
35S-methionine-labeled in vitro-translated NMHC-IIA was
incubated with either GST alone (lane 2), GST-Dab2 (aa 1–770)
(lane 3), GST-C-Dab2 (aa 447–770) (lane 4), GST-N-Dab2 (aa 1–446)
(lane 5), or GST-megalin cytoplasmic tail domain (aa 4423–4635)
(lane 6). The precipitates were resolved by 6% SDS-PAGE and
detected by autoradiography. Lane 1 is equal to 10% of the input
into the interaction assay. Size markers indicate molecular mass in
kilodaltons.
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Figure 5 | Immunoprecipitation of the megalin minireceptor,
Dab2 and NMHC-IIA coexpressed in COS-7 cells, showing that
NMHC-IIA and megalin are linked by interactions with Dab2.
(a) COS-7 cells were transfected with the expression plasmids
encoding GFP-tagged NMHC-IIA (lanes 1, 2, 4, and 5), V5-tagged
Dab2 (lanes 1, 3, 4, and 5) and megalin minireceptor (lanes 1, 2, 3,
and 5). Cell lysates were immunoprecipitated with a polyclonal
anti-megalin antibody (upper two panels, lanes 2–5). The
precipitates were resolved by 6% SDS-PAGE followed by
immunoblotting with anti-GFP and anti-V5 antibodies. Lower four
panels demonstrate that the transfected cells expressed GFP-
NMHC-IIA, V5-Dab2 and megalin minireceptor at comparable
levels, and that V5-Dab2-untransfected cells expressed Dab2
endogenously at a low level. (b) An analogous
immunoprecipitation was carried out with an anti-GFP antibody,
followed by immunoblotting with an anti-megalin antibody
(LBD4). Size markers indicate molecular mass in kilodaltons.
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megalin.39 Blebbistatin treatment of the cells inhibited
lactoferrin degradation by approximately 18 and 42% after
two and four hours of incubation, respectively, compared
with vehicle-only controls (Figure 6). Associations of the
lactoferrin ligand to cells were also reduced by blebbistatin.
Furthermore, we investigated the effects of blebbistatin on
the endocytic trafficking of megalin by using monoclonal
anti-megalin IgG (20B) that binds to megalin on L2 cell
surface and tracking its endocytic pathway.12 We found that
the internalization of 20B-bound megalin into L2 cells was
much decreased by treating the cells with blebbistatin
(Supplementary Figures S5 and S6). Blebbistatin was
found not to affect fluid-phase endocytosis (Supplementary
Figure S7) and did not induce apparent toxicity in L2 cells
(Supplementary Figure S8). These data suggest that non-
muscle myosin II activity is a necessary component of
megalin’s endocytic functions.
DISCUSSION
In this study, we investigated protein complexes associated
with Dab2-mediated trafficking of megalin, a multiligand
endocytic receptor in PTC, by screening and characterizing
proteins that co-immunoprecipitate with both Dab2 and
megalin. We found that NMHC-IIA binds directly to the
C-terminal region of Dab2 and is linked to megalin through
the Dab2 interaction.
Class II myosins (conventional type) are hexameric two-
headed motor proteins composed of two heavy chains and
two pairs of light chains. Dimerization of the heavy chains
yields a polar structure; the N-termini form two globular
heads with actin- and ATP-binding domains required for
motor activity, whereas the a-helical C-termini form a single
rod-like coiled-coil tail, which allows the molecules to
polymerize into bipolar filaments. In humans, there are
three non-muscle myosin II heavy chains (IIA, IIB, and IIC)
encoded by separate genes (MYH9, MYH10, and MYH14,
respectively).25 Besides their well-characterized roles in
contraction and force production in muscles, Class II
myosins are also required for cytoskeleton organization and
motility of non-muscle cells.40 There are also reports
suggesting the involvement of Class II myosins in vesicle
trafficking,41,42 but the mechanisms have been largely
undetermined.
Genetic alterations of NMHC-IIA are known to cause
inherited human diseases, known as MYH9 disorders, that
are characterized by giant platelets, thrombocytopenia and
granulocyte inclusions.43,44 The spectrum of diseases due to
mutations in MYH9 includes May-Hegglin anomaly, Sebas-
tian syndrome, Fechtner syndrome and Epstein syn-
drome.43–46 Notably, these disorders also present with
Alport’s syndrome-like symptoms including kidney disease,
sensorineural deafness and cataracts.45,47 The manifestation
of kidney disease in MYH9 disorders indicates the impor-
tance of NMHC-IIA in maintaining normal kidney func-
tions, which has been also verified by two recent genome-
wide scan analyses.48,49
Dab2 is an adaptor protein that plays a pivotal role in
megalin-mediated endocytosis.19 Recently, another member
of the myosin family, myosin VI (a reverse-direction
molecular motor) was also localized to the base of PTC
microvilli23 and was found to interact with the C-terminal
region of Dab2.20,21 This suggests Dab2’s complex role of
binding to different types of myosins to regulate endocytosis
or scaffolding of megalin in PTC. How much myosin VI
contributes to megalin functions in PTC has not been
determined. Myosin VI knockout mice (used as an animal
model for deafness)50 showed no apparent proteinuria,
although proximal tubular uptake of intravenously injected
horseradish peroxidase was slow in the kidneys of these
mice.51 Further investigation is needed to clarify roles of
various myosin proteins in PTC, as well as the functional
associations among them. The mechanism of Dab2 binding
to different myosins also requires further study.
This study demonstrates that megalin and NMHC-IIA are
linked by interactions with Dab2 in PTC. This finding
provides novel evidence of an association between an
endocytic receptor and motor proteins through an inter-
mediary adaptor protein, and it represents a significant
advance in our understanding of megalin-associated multi-
protein complexes and the endocytosis mechanisms.
MATERIALS AND METHODS
Antibodies
A rabbit polyclonal antibody raised against purified rat megalin was
prepared as described.33 A rabbit polyclonal antibody (LBD4) raised
against the fourth LBD of rat megalin,52 and a monoclonal anti-rat
megalin antibody (20B)53 were provided by Dr MG Farquhar
(University of California, San Diego, USA). Polyclonal anti-Dab2
IgG (C-20), anti-Rab 5A IgG (S-19) and anti-GRP 78 IgG were
purchased from Santa Cruz Biotechnology Inc. (CA, USA),
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Figure 6 | Blebbistatin-mediated inhibition of nonmuscle
myosin II impairs uptake and degradation of lactoferrin in L2
cells. For cellular uptake and degradation assays, cultured L2 cells
were incubated with 125I-lactoferrin, an endocytic ligand of
megalin, for 2 or 4 h in the absence or presence of 100 mM
blebbistatin, a specific nonmuscle myosin II inhibitor. Values
(means±s.d., n¼ 4) are expressed relative to the levels in the
control cells after 2 h incubation. *Po0.01.
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monoclonal anti-Dab2 IgG and monoclonal anti-GFP IgG from BD
BioSciences (San Jose, CA, USA), polyclonal anti-myosin IgG which
binds only to NMHC-IIA from Biomedical Technologies Inc.
(Stoughton, MA, USA), polyclonal anti-NMHC-IIA IgG from
Covance (Princeton, NJ, USA), monoclonal anti-Trans-Golgi Net-
work 38 (TGN 38) IgG from Affinity Bioreagents (Golden, CO,
USA), and monoclonal anti-V5 IgG from Invitrogen (Carlsbad, CA,
USA).
Cell culture
IRPTC54 were maintained in Earle’s minimum essential medium
supplemented with 5% fetal calf serum, 20 mM HEPES, pH 7.5, and
10 mM non-essential amino acids solution at 371C and 5% CO2.
COS-7 cells and megalin-expressing rat yolk sac tumor-derived L2
cells33 were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum. Cell culture
reagents were obtained from Invitrogen except as indicated.
SDS-PAGE and immunoblotting
Protein concentrations were determined using the bicinchoninic
acid assay kit (Pierce, Rockford, IL, USA). Samples were resolved by
4–15% gradient or 6% SDS-PAGE under reducing conditions,
transferred to polyvinylidene difluoride membranes (Bio-Rad
Laboratories, Hercules, CA, USA), and incubated with primary
antibodies for 2 h at room temperature. After 1-h incubation in
horseradish peroxidase-conjugated goat anti-rabbit, anti-mouse or
TrueBlot (eBioscience, San Diego, CA, USA) IgG (1:3000 dilution),
immunoreactive proteins were detected by enhanced chemilumine-
scence (Super Signal, Pierce).
Immunoprecipitation
Cultured cells were solubilized in lysis buffer (0.5% Triton X-100,
20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA) containing
10 mg/ml leupeptin and 0.5 mM PMSF, and centrifuged at 15,000 g at
41C for 30 min. Non-specific binding proteins were precleared. The
supernatant was then incubated with 2 mg each of polyclonal anti-
megalin, anti-Dab2 (C-20), monoclonal anti-megalin (20B), or anti-
GFP IgG at 41C for 15 h. Ten microliters of Protein A-agarose beads
(Bio-Rad Laboratories) were then added to bind antibodies and
associated proteins, and the beads were washed three times with lysis
buffer and two times with PBS. Bound immune complexes were
eluted from the beads by denaturation in 1 Laemmli sample buffer
at 951C for 3 min, and then resolved by SDS-PAGE, followed by
immunoblotting in some cases.
Mass spectrometry
Proteins within individual gel slices were digested directly with
trypsin as described earlier.55 The masses of the resulting proteolytic
peptides were measured at APRO Life Science Institute Inc. (Naruto,
Tokushima, Japan), using LC-MS/MS as described earlier.56 Peptide
mass maps acquired from each band were submitted as query to the
Mascot search engine for identity matching.
Plasmids and transfection
The plasmid pLNCX-M4 was designed to express a megalin
minireceptor cDNA that encodes the fourth LBD through the
cytoplasmic domain of rat megalin.27 pCMV-GFP-NMHC-IIA,
which expresses GFP-tagged human NMHC-IIA57 was provided by
Dr RS Adelstein (NIH). Human Dab2 cDNA was purchased from
Invitrogen, and the sequence encoding the V5 epitope was added to
the 50end (V5-Dab2) using Gateway technology (Invitrogen). COS-7
cells were cultured overnight, and transfected using Fugene 6
(Roche, Mannheim, Germany). After 40 h, the transfected cells were
prepared for immunoprecipitation.
In vitro pull-down assays
To generate GST fusion proteins, cDNAs encoding full-length
human Dab2 (aa 1–770), Dab2 N terminus (N-Dab2, aa 1–446),
Dab2 C terminus (C-Dab2, aa 447–770) and the cytoplasmic
domain of rat megalin (aa 4423–4635) were amplified by PCR and
inserted into pGEX-6p-1 (Amersham Biosciences, Piscataway, NJ,
USA). GST fusion proteins or GST alone were expressed in the
Origami or Rosetta-gami (DE3) pLysS Escherichia coli strain
(Novagen, Madison, WI, USA), and immobilized on glutathione-
agarose beads (Amersham Biosciences) as described by the
manufacturer. 35S-labeled full-length human NMHC-IIA was
produced from pCMV-NMHC-IIA using the TNT T7 rabbit
reticulolysate Quick-Coupled Transcription/Translation system
(Promega, Madison, WI, USA) in the presence of [35S] methionine,
according to the manufacturer’s instructions. In vitro-translated
products were incubated with 5 mg of each GST fusion protein
immobilized on glutathione-agarose beads in binding buffer (0.5%
Triton X-100, 20 mM HEPES, pH 7.4, 150 mM NaCl, 2 mM CaCl2,
1 mM dithiothreitol, 0.1% bovine serum albumin, and 10 mg/ml
leupeptin) for 15 h at 41C with gentle rocking. Beads were then
washed four times in the same buffer without bovine serum
albumin, after which bound proteins were eluted by boiling for
3 min in 25 ml Laemmli sample buffer. Proteins were resolved by 6%
SDS-PAGE and visualized using a Bio-imaging analyzer (BAS5000,
Fujifilm, Tokyo, Japan).
Subcellular fractionation of rat renal cortices on sucrose
density gradients
Kidneys of male Sprague–Dawley rats (B300 g body wt) were
perfused with ice-cold PBS. After excision, renal cortices were
dissected in homogenization buffer (0.25 M sucrose, 1 mM EDTA,
10 mM HEPES, pH 7.5) supplemented with protease inhibitor
cocktail, Complete (Roche). Subcellular fractionation was per-
formed as described earlier.58,59 Briefly, renal cortices were
homogenized using a Potter–Elvehjem homogenizer with a teflon
pestle. After 6 up-and-down strokes of the pestle rotating at
600–800 r.p.m., the homogenate was centrifuged at 2000 g for
10 min. The supernatants were loaded on a continuous sucrose
gradient (0.25–2.0 M) prepared with a Gradient Master (Biocomp
Instruments Inc., Fredericton, NB, Canada). The gradient was
centrifuged for 3 h at 25,800 r.p.m. (B80,000 g) in an RPS40T rotor
(Hitachi Koki, Tokyo, Japan) and fractionated at 0.5 ml/tube with a
Piston Gradient Fractionator (Biocomp Instruments Inc.). After
fractionation, proteins in each fraction were analyzed by immuno-
blotting and immunoprecipitation as described above.
Sucrose velocity gradient centrifugation
Velocity gradient sedimentation was carried out according to
Copeland et al.60 Rat renal microsomes were solubilized in lysis
buffer (pH 7.4) containing 20 mM HEPES, 30 mM Tris, 100 mM NaCl,
and 1% Triton X-100. Insoluble material was removed by
centrifugation at 200,000 g for 1 h at 41C. The supernatants were
applied to the top of 5–25% continuous sucrose gradients. After
centrifugation for 12 h at 41C at 38,000 r.p.m. (B150,000 g) in an
RPS40T rotor, the gradients were fractionated as described above.
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Radioiodination
Human lactoferrin (Sigma-Aldrich, Milwaukee, WI, USA) was
radio-iodinated using 1 mCi Na-125I (Amersham Biosciences) and
one Iodo-Bead (Pierce) according to the manufacturer’s instructions.
Free Na-125I was removed from the labeled proteins by binding to a
PD-10 column (Bio-Rad Laboratories). The specific activity of the
resulting purified 125I-lactoferrin was 2.1 106 c.p.m. per mg.
Cellular association and degradation assays
L2 cells were grown to confluence (1 105 cells per well) on 12-well
tissue culture plates coated with 1% gelatin. The cells were washed
two times with DMEM and serum-starved for 1 h in the presence of
0.5% DMSO (vehicle) or 100mM blebbistatin (Calbiochem, San
Diego, CA, USA), and then incubated in DMEM containing 0.1%
ovalbumin with 125I-lactoferrin (1.0mg/ml). Blebbistatin or DMSO
was maintained throughout the incubation period. After 2 or 4 h
incubation, trichloroacetic acid (TCA) was added to the culture
medium to a final concentration of 15% to precipitate labeled
proteins, and the radioactivity of the TCA-soluble degradation
products was quantified by g counting. To correct for iodine liberated
from 125I-labeled ligands, the level of TCA-soluble radioactivity in
medium incubated without cells was subtracted from that found in
the samples. The cells were washed with ice-cold PBS and solubilized
in 1 N NaOH to measure cell-associated radioactivity. Statistical
analyses were carried out using the unpaired Student’s t test.
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